Effects of macrolides on antigen presentation and cytokine production by dendritic cells and T lymphocytes

International Journal of Pediatric Otorhinolaryngology

Volumn 71, Issue 2, 2007, Pages 297-305

  Ishida, Yoshiya ^a   Abe, Yusuke ^a   Harabuchi, Yasuaki ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Dendritic cells; Human; Immune responses; Macrolides; T lymphocytes

Indexed keywords

ANTIGEN; BACTERIAL PROTEIN; CLARITHROMYCIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; MACROLIDE; OUTER MEMBRANE PROTEIN; PROTEIN P6; ROXITHROMYCIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; BRONCHIOLITIS; CD4+ T LYMPHOCYTE; CHRONIC BRONCHITIS; CHRONIC RESPIRATORY TRACT DISEASE; CHRONIC SINUSITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG INDICATION; DRUG MECHANISM; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPHARMACOLOGY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIGEN PRESENTATION; BACTERIAL OUTER MEMBRANE PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CLARITHROMYCIN; CYTOKINES; DENDRITIC CELLS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HUMANS; INTERLEUKIN-8; INTERLEUKINS; MACROLIDES; PREDNISOLONE; ROXITHROMYCIN;

EID: 33845977751     PISSN: 01655876     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijporl.2006.10.016     Document Type: Article

References (32)

1. Cole P.J. Microbial-host interactions in the airways in chronic respiratory infection. Clin. Ther. 13 (1991) 194-198
2. Sawaki M., Mikami R., Mikasa K., Kunimatsu M., Ito S., and Narita N. The long term chemotherapy with erythromycin in chronic lower respiratory tract infections-second report: including cases with Pseudomonas infections. Kansenshogaku Zasshi 60 (1986) 45-50
3. Yamamoto M., Kondo A., Tamura M., Izumi T., Ina Y., and Noda M. Long-term therapeutic effects of erythromycin and newquinolone antibacterial agents on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 28 (1990) 1305-1313
4. Kudoh S., Uetake T., Hagiwara K., Hirayama M., Hus L.H., Kimura H., et al. Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 25 (1987) 632-642
5. Nagai H., Shishido H., Yoneda R., Yamaguchi E., Tamura A., and Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 58 (1991) 145-149
6. Fujii T., Kadota J., Kawakami K., Iida K., Shirai R., Kaseda M., et al. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 50 (1995) 1246-1252
7. Wallwork B., Coman W., Feron F., Mackay-Sim A., and Cervin A. Clarithromycin and prednisolone inhibit cytokine production in chronic rhinosinusitis. Laryngoscope 112 (2002) 1827-1830
8. Iino Y., Toriyama M., Kudo K., Natori Y., and Yuo A. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. Ann. Otol. Rhinol. Laryngol. Suppl. 157 (1992) 16-20
9. Takeshita K., Yamagishi I., Harada M., Otomo S., Nakagawa T., and Mizushima Y. Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages. Drugs Exp. Clin. Res. 15 (1989) 527-533
10. Fujita K., Shimizu T., Majima Y., and Sakakura Y. Effects of macrolides on interleukin-8 secretion from human nasal epithelial cells. Eur. Arch. Otorhinolaryngol. 257 (2000) 199-204
11. Suzuki H., Shimomura A., Ikeda K., Furukawa M., Oshima T., and Takasaka T. Inhibitory effect of macrolides on interleukin-8 secretion from cultured human nasal epithelial cells. Laryngoscope 107 (1997) 1661-1666
12. Abe S., Nakamura H., Inoue S., Takeda H., Saito H., Kato S., et al. Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 22 (2000) 51-60
13. Desaki M., Takizawa H., Ohtoshi T., Kasama T., Kobayashi K., Sunazuka T., et al. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem. Biophys. Res. Commun. 267 (2000) 124-128
14. Mukaida N., Gussella G.L., Kasahara T., Ko Y., Zachariae C.O., Kawai T., et al. Molecular analysis of the inhibition of interleukin-8 production by dexamethasone in a human fibrosarcoma cell line. Immunology 75 (1992) 674-679
15. Mukaida N., Morita M., Ishikawa Y., Rice N., Okamoto S., Kasahara T., et al. Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression. J. Biol. Chem. 269 (1994) 13289-13295
16. Okamoto S., Mukaida N., Yasumoto K., Rice N., Ishikawa Y., Horiguchi H., et al. The interleukin-8 AP-1 and kappa B-like sites are genetic end targets of FK506-sensitive pathway accompanied by calcium mobilization. J. Biol. Chem. 269 (1994) 8582-8589
17. Akira S., Takeda K., and Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2 (2001) 675-680
18. Iino Y., Sasaki Y., Kojima C., and Miyazawa T. Effect of macrolides on the expression of HLA-DR and costimulatory molecules on antigen-presenting cells in nasal polyps. Ann. Otol. Rhinol. Laryngol. 110 (2001) 457-463
19. Keicho N., Kudoh S., Yotsumoto H., and Akagawa K.S. Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. J. Antibiot. (Tokyo) 46 (1993) 1406-1413
20. Asano K., Kamakazu K., Hisamitsu T., and Suzaki H. Modulation of Th2 type cytokine production from human peripheral blood leukocytes by a macrolide antibiotic, roxithromycin, in vitro. Int. Immunopharmacol. 1 (2001) 1913-1921
21. Seto H., Asano K., and Susaki H. Inhibitory effect of roxithromycin, a macrolide antibiotic, on Th2 cytokine production. Jpn. J. Antibiot. 54 Suppl. C (2001) 76-79
22. Kobayashi H., Wood M., Song Y., Appella E., and Celis E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res. 60 (2000) 5228-5236
23. Harabuchi Y., Faden H., Yamanaka N., Duffy L., Wolf J., and Krystofik D. Human milk secretory IgA antibody to nontypeable Haemophilus influenzae: possible protective effects against nasopharyngeal colonization. J. Pediatr. 124 (1994) 193-198
24. Harabuchi Y., Faden H., Yamanaka N., Duffy L., Wolf J., and Krystofik D. Nasopharyngeal colonization with nontypeable Haemophilus influenzae and recurrent otitis media. Tonawanda/Williamsville Pediatrics. J. Infect. Dis. 170 (1994) 862-866
25. Kodama H., Faden H., Harabuchi Y., Kataura A., Bernstein J.M., and Brodsky L. Cellular immune response of adenoidal and tonsillar lymphocytes to the P6 outer membrane protein of non-typeable Haemophilus influenzae and its relation to otitis media. Acta Otolaryngol. 119 (1999) 377-383
26. Abe Y., Murphy T.F., Sethi S., Faden H.S., Dmochowski J., Harabuchi Y., et al. Lymphocyte proliferative response to P6 of Haemophilus influenzae is associated with relative protection from exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 165 (2002) 967-971
27. Karalus R.J., and Murphy T.F. Purification and characterization of outer membrane protein P6, a vaccine antigen of non-typeable Haemophilus influenzae. FEMS Immunol. Med. Microbiol. 26 (1999) 159-166
28. Munson Jr. R.S., and Granoff D.M. Purification and partial characterization of outer membrane proteins P5 and P6 from Haemophilus influenzae type b. Infect. Immun. 49 (1985) 544-549
29. Badr W.H., Loghmanee D., Karalus R.J., Murphy T.F., and Thanavala Y. Immunization of mice with P6 of nontypeable Haemophilus influenzae: kinetics of the antibody response and IgG subclasses. Vaccine 18 (1999) 29-37
30. Koyama M., Tateno M., Shirotsuka M., Yamamoto T., Hirayama M., Saitoh K., et al. Absorption, metabolism and excretion of RU 28965 in humans. Chemotherapy 36 (1988) 164-183
31. Suwa T., Urano H., Kodama T., and Nakamura M. Metabolic fate of TE-031 (A-56268) (VIII). Chemotherapy 36 (1988) 921-932
32. Tanaka T., and Miyachi Y. Measurement of synthetic steroid, and meaning on clinical. Japanese 4 (1978) 822-823